For patients with HoFH, the largest breakthrough has come from therapies that bypass the LDLR, enabling clinicians to treat all patients with HoFH irrespective of their genotype with lipoprotein apheresis as last treatment option. The gene discussed is LDLR; the disease is homozygous familial hypercholesterolemia.